William Blair analyst Andy Hsieh has maintained their neutral stance on NKTR stock, giving a Hold rating on November 13.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andy Hsieh has given his Hold rating due to a combination of factors related to the upcoming trial results and the ongoing research in other areas. The anticipated results from the Phase IIb REZOLVE-AA trial for rezpeg in treating severe to very severe alopecia areata are expected in December. The primary focus of this trial is the change in the Severity of Alopecia Tool (SALT) score, with a base case expectation that 12%-18% of patients will achieve a significant improvement, similar to existing treatments like Olumiant.
Despite this, the overall outlook remains neutral as the results are not expected to significantly outperform current benchmarks. Additionally, the investigation of rezpeg in atopic dermatitis, with results expected in early 2026, remains a key area of interest for investors. This ongoing research and the uncertainty surrounding the trial outcomes contribute to the Hold rating, as the potential for significant advancements or setbacks remains balanced.
In another report released on November 13, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $58.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTR in relation to earlier this year.